Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) has 14 years of Non-Current Deferred Tax Liability data on record, last reported at $629.0 million in Q3 2025.
- For Q3 2025, Non-Current Deferred Tax Liability fell 20.55% year-over-year to $629.0 million; the TTM value through Sep 2025 reached $629.0 million, down 20.55%, while the annual FY2024 figure was $676.7 million, 51.16% down from the prior year.
- Non-Current Deferred Tax Liability reached $629.0 million in Q3 2025 per JAZZ's latest filing, down from $682.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.5 billion in Q4 2022 and bottomed at $109.9 million in Q1 2021.
- Average Non-Current Deferred Tax Liability over 5 years is $948.0 million, with a median of $910.7 million recorded in 2023.
- Peak YoY movement for Non-Current Deferred Tax Liability: surged 1011.84% in 2022, then tumbled 51.16% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.3 billion in 2021, then rose by 14.81% to $1.5 billion in 2022, then fell by 7.2% to $1.4 billion in 2023, then crashed by 51.16% to $676.7 million in 2024, then fell by 7.05% to $629.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $629.0 million in Q3 2025, $682.1 million in Q2 2025, and $670.8 million in Q1 2025.